Comparative efficacy of rituximab in biologic/targeted synthetic DMARD-naive versus exposed rheumatoid arthritis patients: a retrospective cohort study

Abstract

Objective: To compare the efficacy and safety of rituximab in patients with rheumatoid arthritis (RA) who were either biologic/targeted synthetic DMARD (bDMARD/tsDMARD)-naive or previously exposed. Methods: In this retrospective cohort study, 120 RA patients treated with rituximab between June 2020 and December 2023 were included. Patients were categorized as bDMARD/tsDMARD-naive (n=66) or -exposed (n=54). Clinical efficacy was assessed by change in Disease Activitity Score 28 (DAS28)-CRP and the proportion achieving low disease activity (LDA; DAS28-CRP <3.2) after treatment. Safety outcomes included infusion-related reactions (IRRs), infections, and hypogammaglobulinemia. Results: The naive group showed significantly greater improvement in disease activity (ΔDAS28-CRP: 2.5 vs. 1.9, p=0.001) and higher LDA achievement (62.1% vs. 46.2%, p=0.030) compared to the exposed group. Rates of IRRs (16.6% vs. 18.5%, p=0.820), infections (1.5% vs. 1.9%, p=0.880), and hypogammaglobulinemia were comparable between groups. Most IRRs were mild (grade 1–2); only one serious IRR occurred, with no cases requiring prolonged hospitalization. One patient in the exposed group experienced hepatitis B reactivation, managed effectively with antiviral therapy. Primary and secondary inefficacy were the most common reasons for rituximab discontinuation, with no significant differences between groups. Conclusion: Rituximab demonstrated superior efficacy in bDMARD/tsDMARD-naive RA patients, while maintaining a comparable safety profile to that in previously exposed patients. These findings support the potential benefit of using Rituximab earlier in the treatment sequence for selected RA patients.

Keywords

• Rituximab
• rheumatoid arthritis
• biologic drug
• treatment outcome
• infusion-related reactions

References

1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423(6937):356-61. doi:10.1038/nature01661.
2. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023-38. doi:10.1016/S0140-6736(16)30173-8.
3. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572-81. doi:10.1056/NEJMoa032534.
4. van Vollenhoven RF, Emery P, Bingham CO 3rd, Keystone EC, Fleischmann RM, Furst DE, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72(9):1496-1502. doi:10.1136/annrheumdis-2012-201956.
5. Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3-18. doi:10.1136/ard-2022-223356.
6. Dorner T, Burmester GR. The role of B cells in rheumatoid arthritis: Mechanisms and therapeutic targets. Curr Opin Rheumatol. 2003;15(3):246-52. doi:10.1097/00002281-200305000-00012.
7. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(2):613-20. doi:10.1002/art.21617.
8. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54(9):2793-2806. doi:10.1002/art.22025.

9. Aletaha D, Neogi T, Sliman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: An ACR/EULAR collaborative initiative. Arthritis Rheum. 2010;62(9):2569-81. doi:10.1002/art.27584.
10. Fransen J, van Riel PLCM. The Disease Activity Score and the EULAR Response Criteria. Rheum Dis Clin North Am. 2009;35(4):745-57. doi:10.1016/j.rdc.2009.10.001.
11. Aletaha D, Ward MM, Machold KP, Nell VP, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum. 2005;52(9):2625-36.
12. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. U.S. Department of Health and Human Services, National Institutes of Health;2017. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf. Accessed April 3, 2023.
13. Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, et al. Efficacy and safety of different doses and retreatment of rituximab: A randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (SERENE). Ann Rheum Dis. 2010;69(9):1629-35. doi:10.1136/ard.2009.119933.
14. Teng YK, Levarht EW, Toes RE, Huizinga TW, van Laar JM. Residual inflammation after rituximab treatment is associated with synovial plasma infiltration and enhanced B cell repopulation. Ann Rheum Dis. 2009;68(6):1011-6. doi:10.1136/ard.2008.092791.
15. Tak PP, Rigby WF, Rubbert-Roth A, Peterfy CG, van Vollenhoven RF, Stohl W, et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis. 2011;70(1):39-46. doi:10.1136/ard.2010.137703.
16. van Vollenhoven RF, Emery P, Bingham CO 3rd, Keystone EC, Fleischmann R, Furst DE, et al. Long-term safety of patients receiving rituximab in RA clinical trials. J Rheumatol. 2010;37(3):558-67. doi:10.3899/jrheum.090856.
17. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54(5):1390-400. doi:10.1002/art.21778.
18. D’Arena G, Simeon V, Laurenti L, Cimminiello M, Innocenti I, Gilio M, et al. Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of a few clinical and laboratory parameters: Results from a retrospective, multicenter study of 374 patients. Leuk Lymphoma. 2017;58(11):2633-41. doi:10.1080/10428194.2017.1306648.
19. Frasca D, Diaz A, Romero M, Landin AM, Blomberg BB. Age effects on B cells and humoral immunity in humans. Ageing Res Rev. 2011;10(3):330-5. doi:10.1016/j.arr.2010.08.004.
20. Pekdiker M. The frequency and associated factors of infusion-related reactions to rituximab for patients with rheumatoid arthritis. Interdiscip Med J. 2023;14(49):105-10. doi:10.17944/interdiscip.1351896.
21. Salmon JH, Perotin JM, Morel J, Dramé M, Cantagrel A, Ziegler LE, et al. Serious infusion-related reaction after rituximab, abatacept, and tocilizumab in rheumatoid arthritis: Prospective registry data. Rheumatology (Oxford). 2018;57(1):134-9. doi:10.1093/rheumatology/kex403.
22. Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP, et al. Monoclonal antibody-associated progressive multifocal leukoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: A Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol. 2009;10(8):816-24. doi:10.1016/S1470-2045(09)70161-5.
23. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol.. 2009;27(4):605-11. doi:10.1200/JCO.2008.18.0182.
24. Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: A systematic review and meta-analysis. Lancet. 2015;386(9990):258-65. doi:10.1016/S0140-6736(14)61704-9.
25. Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist. 2008 Jun;13(6):725-32. doi: 10.1634/theoncologist.2008-0012.
26. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial. Lancet. 2008;372(9636):375-82. doi:10.1016/S0140-6736(08)61056-2.
27. Porter D, van Melckebeke J, Dale J, Messow CM, McConnachie A, Walker A, et al. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Lancet. 2016 ;388(10041):239-47. doi: 10.1016/S0140-6736(16)00380-9.
28. Emery P, Gottenberg JE, Rubbert-Roth A, Sarzi-Puttini P, Choquette D, Taboada VM, et al. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. Ann Rheum Dis. 2015;74(6):979-84. doi: 10.1136/annrheumdis-2013-203993.
29. Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924-39. doi:10.1002/acr.24596.